Blockchain Registration Transaction Record
Alzamend Neuro Partners with MGH for Phase II Trial of Next-Generation Lithium Therapeutic Drug Candidate for Bipolar Disorder
Alzamend Neuro, Inc. (NASDAQ:ALZN) partners with MGH for Phase II trial of next-generation lithium therapeutic drug candidate for bipolar disorder and Alzheimer's disease, potentially revolutionizing mental health treatment.
This news matters because it highlights the potential breakthrough in next-generation treatments for mental health disorders, impacting millions of people worldwide. The partnership with MGH for clinical trials could lead to improved treatment options for bipolar disorder and Alzheimer's disease, offering hope to millions of patients and their families.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0x9318ae22df243a26eec2d768a2004843a5c2a27b6594b0a563166db3ba663e52 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | markJU29-45c9f521d02a8673b5eb10a77be30952 |